Literature DB >> 28281226

Polypharmacotherapy and blood products as risk factors for venous thromboembolism in postsurgical patients: a case-control study.

Alenka Premuš Marušič1,2, Daniel Petrovič3, Aleš Mrhar2, Igor Locatelli4.   

Abstract

Background After surgical procedures, patients are at high risk of developing venous thromboembolism, clinically manifested as deep vein thrombosis (DVT) or pulmonary embolism (PE). Objective To evaluate the influence of polypharmacotherapy, comorbidity, drug treatments, packed red blood cells application, adequacy of thromboprophylaxis, and patient characteristics on the occurrence of DVT or PE in postsurgical patients. Setting The surgical department at Murska Sobota General Hospital, Slovenia. Methods In this retrospective case control study, the records of 286 surgical patients were analysed: DVT or PE group (n = 144) and control group (n = 142). The number of prescribed drugs and drug-drug interactions were reviewed, together with prescription of low-molecular-weight heparins. The odds ratios (OR) of risk factors for DVT or PE were calculated using a multivariable logistic regression model. Main outcome measure Risk factors assessment for the occurrence of DVT or PE in surgical patients. Results Polypharmacotherapy (OR 2.02, 95% CI 1.03-3.96, p = 0.040) and packed red blood cells application (OR 3.44, 95% CI 1.46-8.10, p = 0.005) were associated with an increased risk of PE or DVT after surgery. Inadequate thromboprophylaxis with low-molecular-weight heparins significantly increased the likelihood of DVT or PE (OR 2.50, 95% CI 1.41-4.43, p = 0.002). There were no differences between the groups concerning the treatment with nonsteroidal anti-inflammatory drugs, benzodiazepines or antipsychotics. Conclusions Patients with polypharmacotherapy and patients receiving red blood cells should be monitored more closely after surgery as they are more likely to develop DVT or PE.

Entities:  

Keywords:  Drug interactions; Packed red blood cells; Polypharmacotherapy; Prevention; Slovenia; VTE-prophylaxis; Venous tromboembolism

Mesh:

Substances:

Year:  2017        PMID: 28281226     DOI: 10.1007/s11096-017-0441-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  36 in total

1.  Risk factors for adverse drug events among nursing home residents.

Authors:  T S Field; J H Gurwitz; J Avorn; D McCormick; S Jain; M Eckler; M Benser; D W Bates
Journal:  Arch Intern Med       Date:  2001-07-09

2.  More cases of SIADH with fluoxetine.

Authors:  B J Cohen; M Mahelsky; L Adler
Journal:  Am J Psychiatry       Date:  1990-07       Impact factor: 18.112

Review 3.  Virchow's triad revisited: abnormal flow.

Authors:  Gordon D O Lowe
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

Review 4.  How a damaged blood vessel wall contibutes to thrombosis and hypertenasion.

Authors:  Andrew D Blann
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

5.  Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.

Authors:  D L Disch; M L Greenberg; P T Holzberger; D J Malenka; J D Birkmeyer
Journal:  Ann Intern Med       Date:  1994-03-15       Impact factor: 25.391

6.  Risk of venous thrombosis in patients with major illnesses: results from the MEGA study.

Authors:  G Ocak; C Y Vossen; M Verduijn; F W Dekker; F R Rosendaal; S C Cannegieter; W M Lijfering
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

Review 7.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

8.  Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Jonathan P Piccini; Anne S Hellkamp; Jeffrey B Washam; Richard C Becker; Günter Breithardt; Scott D Berkowitz; Jonathan L Halperin; Graeme J Hankey; Werner Hacke; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Keith A A Fox; Manesh R Patel
Journal:  Circulation       Date:  2015-12-16       Impact factor: 29.690

9.  Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1993-12       Impact factor: 24.094

10.  Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study.

Authors:  Valentino Conti; Mauro Venegoni; Alfredo Cocci; Ida Fortino; Antonio Lora; Corrado Barbui
Journal:  BMC Psychiatry       Date:  2015-04-29       Impact factor: 3.630

View more
  3 in total

Review 1.  Impact of drugs on venous thromboembolism risk in surgical patients.

Authors:  Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič
Journal:  Eur J Clin Pharmacol       Date:  2019-02-05       Impact factor: 2.953

Review 2.  Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence.

Authors:  Anna K Jönsson; Johan Schill; Hans Olsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

3.  Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies.

Authors:  Yinzhao Liu; Jun Xu; Kacey Fang; Yue Xu; Ju Gao; Chao Zhou; Xiaowei Tang; Xinyu Fang; Jiu Chen; Chunming Xie; Fuquan Zhang; Xiangrong Zhang; Congjie Wang
Journal:  Ther Adv Psychopharmacol       Date:  2021-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.